Venu Bathini to Male
This is a "connection" page, showing publications Venu Bathini has written about Male.
Connection Strength
0.128
-
Wang X, Mathew C, Korapati S, Bathini VG. Successful Long-term Anticoagulation with Enoxaparin in a Patient with a Mechanical Heart Valve. Pharmacotherapy. 2020 02; 40(2):174-177.
Score: 0.040
-
Saini NY, Bathini V. Large granular lymphocytic leukemia-associated peripheral neuropathy. Ann Hematol. 2018 Aug; 97(8):1501-1504.
Score: 0.035
-
Zhu X, Jamshed S, Zou J, Azar A, Meng X, Bathini V, Dresser K, Strock C, Yalamarti B, Yang M, Tomaszewicz K, Tjionas G, Mochel MC, Hutchinson L, Bledsoe JR. Molecular and immunophenotypic characterization of anal squamous cell carcinoma reveals distinct clinicopathologic groups associated with HPV and TP53 mutation status. Mod Pathol. 2021 05; 34(5):1017-1030.
Score: 0.011
-
Philip PA, Lacy J, Portales F, Sobrero A, Pazo-Cid R, Manzano Mozo JL, Kim EJ, Dowden S, Zakari A, Borg C, Terrebonne E, Rivera F, Sastre J, Bathini V, L?pez-Trabada D, Asselah J, Saif MW, Shiansong Li J, Ong TJ, Nydam T, Hammel P. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol. 2020 03; 5(3):285-294.
Score: 0.010
-
Zhu X, Salhab M, Tomaszewicz K, Meng X, Mathew C, Bathini V, Switzer B, Walter O, Cosar EF, Wang X, Lambert LA, Hutchinson LM. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms. Hum Pathol. 2019 03; 85:260-269.
Score: 0.009
-
Kodali S, Bathini V, Rava P, Tipirneni E. Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil. J Gastrointest Cancer. 2017 Mar; 48(1):66-69.
Score: 0.008
-
Li T, Piperdi B, Walsh WV, Kim M, Beckett LA, Gucalp R, Haigentz M, Bathini VG, Wen H, Zhou K, Pasquinelli PB, Gajavelli S, Sreedhara M, Xie X, Lara PN, Gandara DR, Perez-Soler R. Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):60-67.
Score: 0.008
-
Piperdi B, Walsh WV, Bradley K, Zhou Z, Bathini V, Hanrahan-Boshes M, Hutchinson L, Perez-Soler R. Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer. J Thorac Oncol. 2012 Jun; 7(6):1032-40.
Score: 0.006